SPRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SPRO is not a good buy right now for an impatient trader. The tape is still weak (bearish MACD expansion), fundamentals are deteriorating (sharp YoY revenue decline in 2025/Q3), and insiders have been meaningfully selling. While the stock is near support and technically oversold enough to bounce, there is no Intellectia buy signal today and no near-term catalyst in the news flow to justify stepping in immediately.
Price/Trend: SPRO is trading at 2.185 (-2.89%), sitting right on a key support band (S2=2.181) after slipping below S1 (2.243). This is a fragile area: a clean break below ~2.18 would be technically damaging, while a bounce would first need to reclaim the pivot (2.342) and then R1 (2.441). Momentum: MACD histogram is -0.0302 and negatively expanding, indicating bearish momentum is strengthening rather than bottoming. RSI: RSI_6 at 25.051 suggests the stock is oversold/washed-out short term, which can support a reflex bounce—but oversold alone is not a buy signal when MACD is still deteriorating. Moving Averages: Converging MAs suggest compression/indecision, but with momentum still bearish. Pattern-based forward odds: Similar-pattern stats imply muted/negative drift (next month ~-0.1%), offering no strong edge for an immediate entry.
Intellectia Proprietary Trading Signals
plus price sitting on major support (~2.
can produce a quick bounce.
reflects bullish positioning skew toward calls.
Momentum: Bearish MACD histogram is below zero and expanding negatively, suggesting the down-move is still in control.
Insiders: Insiders are selling, with selling activity up ~486% over the last month—an unfavorable near-term signal.
Fundamentals: 2025/Q3 revenue fell sharply (-59.6% YoY), indicating business traction/earnings quality concerns.
Catalyst vacuum: No fresh news in the past week—no clear event-driven reason for an immediate reversal.
High absolute IV (~95.7): The stock is priced for big swings, which often accompanies unstable price action.
Latest quarter: 2025/Q3. Revenue: 5.442M, down -59.60% YoY (material contraction). Net income: -7.382M (loss), with reported YoY change -56.95% (still meaningfully negative profitability). EPS: -0.13, down -59.38% YoY. Gross margin: 100% (typical for certain biotech/revenue-recognition profiles, but it doesn’t offset the steep revenue decline). Overall: The quarter shows weakening top-line and continued losses—does not support a confident buy-today decision without a clear catalyst.
No analyst rating/price target change data was provided, so a verified trend cannot be summarized. From the available inputs, the closest proxy to “Street/pro” behavior is (1) neutral hedge fund activity (no significant trend last quarter) and (2) aggressive insider selling—netting to a cautious-to-bearish professional posture near term. Politicians/Congress: No recent congress trading data available; no politician/influential figure transactions were provided.
